Gusperimus

Gusperimus

Names
Other names N-[2-[4-(3-Aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide
Identifiers
CAS Number	98629-43-7 N
3D model (Jmol)	Interactive image Interactive image
ChEMBL	ChEMBL406117 Y ChEMBL1172736 Y
ChemSpider	49995 Y 82420 S Y
KEGG	D08032 Y
MeSH	gusperimus
PubChem	55362 91272 S
UNII	UJ0ZJ76DO9 Y
InChI InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23) Y Key: IDINUJSAMVOPCM-UHFFFAOYSA-N Y
SMILES NCCCNCCCC[nH]:c(:[o])C(O)[nH]:c(:[o])CCCCCC[nH]:c(:[nH]):[nH2] NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCNC(N)=N
Properties
Chemical formula	C17H37N7O3
Molar mass	387.53 g·mol−1
log P	−0.933
Acidity (pKa)	11.588
Basicity (pKb)	2.409
Pharmacology
ATC code	L04AA19 (WHO)
Routes of administration	Intravenous Subcutaneous
Pharmacokinetics:
Bioavailability	100%
Legal status	℞ (Prescription only)
Related compounds
Related compounds	Dibutylhexamethylenediamine Acetyl hexapeptide-3
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Gusperimus is an immunosuppressive drug. It is a derivative of the antitumor antibiotic spergualin, and inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells.

Gusperimus was developed by Bristol-Myers Squibb. Currently, it is manufactured and sponsored for use as an orphan drug and for clinical studies by the Japanese company Euro Nippon Kayaku. The patent claim (see quotation) is that Gusperimus may be useful for a variety of hyperreactive inflammatory diseases such as autoimmune diseases. The drug is available in vials containing 100 mg each.

There is little information about the pharmacokinetic properties of gusperimus.

The European Commission assigned orphan drug status to Gusperimus in 2001 for the treatment of granulomatosis with polyangiitis, a serious form of vasculitis frequently associated with permanent disability and/or fatal outcome. There have been many cases of patients resistant to all forms of usual treatment responding very well to Gusperimus.

It has been proposed that gusperimus may benefit patients with the neurological disease amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). ALS causes permanent motor deficits and disabilities up to the point that almost all motor functions, including breathing and bladder control, are lost. Patients usually have no intellectual impairments. Currently, there are no results from controlled studies in ALS patients.

There have also been positive and negative anecdotal reports in patients with multiple sclerosis. As with ALS, there are no sufficient studies in MS patients.

Gusperimus may possibly be of use in more common diseases and conditions such as rheumatoid arthritis, Crohn's disease, lupus erythematosus, and the prevention and therapy of transplant rejection or graft-versus-host disease.